Caribou Biosciences, Inc. 10-Q

Item 1. Financial Statements. CARIBOU BIOSCIENCES, INC. AND ITS SUBSIDIARIES Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except share and per share amounts) March 31, 2026 December 31, 2025 ASSETS CURRENT ASSETS Cash and cash equivalents $ 12,057 $ 12,360 Marketable securities, short-term 105,569 126,980 Accounts receivable 227 69 Contract assets 691 1,006 Other receivables 1,445 1,904 Prepaid expenses and other current assets 2,392 2,913 Total current assets 122,381 145,232 NON-CURRENT ASSETS Marketable securities, long-term 1,001 3,505 Property and equipment, net 6,123 6,760 Operating lease, right of use assets 17,356 17,670 Other assets 2,137 2,200 TOTAL ASSETS $ 148,998 $ 175,367 LIABILITIES AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable $ 3,503 $ 5,783 Accrued expenses and other current liabilities 13,889 16,535 Operating lease liabilities, current 1,287 1,201 Deferred revenue 994 1,895 Total current liabilities 19,673 25,414 LONG-TERM LIABILITIES Deferred revenue, net of current portion 1,648 1,752 Operating lease liabilities, non-current 25,659 26,026 Total liabilities 46,980 53,192 COMMITMENTS AND CONTINGENCIES (Note 8) STOCKHOLDERS’ EQUITY Common stock, par value $ 0.0001 per share, 300,000,000 shares authorized as of March 31, 2026, and December 31, 2025; 96,951,234 and 95,143,690 shares issued and outstanding as of March 31, 2026, and December 31, 2025, respectively 10 9 Additional paid-in-capital 723,631 718,578 Accumulated other comprehensive (loss) income ( 23 ) 103 Accumulated deficit ( 621,600 ) ( 596,515 ) Total stockholders’ equity 102,018 122,175 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 148,998 $ 175,367 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 1 Table of Contents CARIBOU BIOSCIENCES, INC. AND ITS SUBSIDIARIES Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share amounts) Three Months Ended March 31, 2026 2025 Licensing and other third-party revenue (including zero and $ 622 from a related party for the three months ended March 31, 2026, and March 31, 2025, respectively) $ 2,397 $ 2,353 Operating expenses: Research and development 20,611 35,531 General and administrative 8,066 9,735 Total operating expenses 28,677 45,266 Loss from operations ( 26,280 ) ( 42,913 ) Other income Other income, net 1,195 2,922 Total other income 1,195 2,922 Net loss ( 25,085 ) ( 39,991 ) Other comprehensive loss Net unrealized loss on available-for-sale marketable securities, net of tax ( 126 ) ( 88 ) Net comprehensive loss $ ( 25,211 ) $ ( 40,079 ) Net loss per share, basic and diluted $ ( 0.26 ) $ ( 0.43 ) Weighted-average common shares outstanding, basic and diluted 95,861,716 92,679,493 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 2 Table of Contents CARIBOU BIOSCIENCES, INC. AND ITS SUBSIDIARIES Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) (in thousands, except share amounts) Common Stock Additional Paid-In Capital Accumulated Other Comprehensive (Loss) Income Accumulated Deficit Total Stockholders’ Equity Shares Amount BALANCE—December 31, 2025 95,143,690 $ 9 $ 718,578 $ 103 $ ( 596,515 ) $ 122,175 Issuances of common stock under ESPP 348,411 — 468 — — 468 Issuances of common stock on exercise of options 6,200 — 9 — — 9 Issuances of common stock in connection with ATM offering, net of offering expenses 1,078,768 1 2,219 — — 2,220 Issuances of common stock upon vesting of RSUs 374,165 — — — — — Stock-based compensation expense — — 2,357 — — 2,357 Net loss — — — — ( 25,085 ) ( 25,085 ) Other comprehensive loss — — — ( 126 ) — ( 126 ) BALANCE—March 31, 2026 96,951,234 $ 10 $ 723,631 $ ( 23 ) $ ( 621,600 ) $ 102,018 BALANCE—December 31, 2024 92,378,577 $ 9 $ 701,077 $ 255 $ ( 448,390 ) $ 252,951 Issuances of common stock under ESPP 408,282 — 468 — — 468 Issuances of common stock upon vesting of RSUs 217,743 — — — — — Stock-based compensation expense — — 3,882 — — 3,882 Net loss — — — — ( 39,991 ) ( 39,991 ) Other comprehensive loss — — — ( 88 ) — ( 88 ) BALANCE—March 31, 2025 93,004,602 $ 9 $ 705,427 $ 167 $ ( 488,381 ) $ 217,222 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 Table of Contents CARIBOU BIOSCIENCES, INC. AND ITS SUBSIDIARIES Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands) Three Months Ended March 31, 2026 2025 CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $ ( 25,085 ) $ ( 39,991 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 649 1,165 Change in fair value of equity securities — 11 Stock-based compensation expense 2,357 3,882 Change in fair value of success payments liability — ( 334 ) Accretion of discounts on investments in marketable securities, net ( 269 ) ( 452 ) Non-cash lease expense 315 490 Changes in operating assets and liabilities: Accounts receivable ( 158 ) 177 Contract assets 315 350 Other receivables 459 ( 17 ) Prepaid expenses and other current assets 522 471 Other assets 63 479 Accounts payable ( 2,220 ) 1,404 Accrued expenses and other current liabilities ( 2,646 ) ( 3,101 ) Deferred revenue, current and long-term ( 1,005 ) ( 996 ) Operating lease liabilities ( 281 ) ( 263 ) Net cash used in operating activities ( 26,984 ) ( 36,725 ) CASH FLOWS FROM INVESTING ACTIVITIES: Proceeds from maturities of marketable securities 46,142 65,955 Purchases of marketable securities ( 22,085 ) ( 15,532 ) Purchases of property and equipment ( 72 ) ( 1,042 ) Net cash provided by investing activities 23,985 49,381 CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from exercise of stock options 9 — Proceeds from issuances of common stock under ESPP 468 468 Proceeds from issuances of common stock related to ATM, net of offering expenses 2,219 — Net cash provided by financing activities 2,696 468 NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH ( 303 ) 13,124 CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — BEGINNING OF PERIOD 12,406 16,339 CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — END OF PERIOD $ 12,103 $ 29,463 RECONCILIATION OF CASH, CASH EQUIVALENTS, AND RESTRICTED CASH Cash and cash equivalents $ 12,057 $ 29,417 Restricted cash 46 46 CASH, CASH EQUIVALENTS, AND RESTRICTED CASH ON THE BALANCE SHEET $ 12,103 $ 29,463 SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Purchases of property and equipment included in accounts payable and accrued expenses $ — $ 115 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 4 Table of Contents CARIBOU BIOSCIENCES, INC. AND ITS SUBSIDIARIES Notes to Condensed Consolidated Financial Statements (Unaudited) 1. Description of the Business, Organization, and Liquidity Business and Organization Caribou Biosciences, Inc. (“Company” or “we”) is a clinical-stage C lustered R egularly I nterspaced S hort P alindromic R epeats (“CRISPR”) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our genome-editing platform is based on our novel chRDNA ( C RISPR h ybrid R NA- DNA , pronounced “chardonnay”) technology, which enables more precise genome editing of allogeneic cell therapies. Our allogeneic, or off-the-shelf, chimeric antigen receptor (“CAR”)-T (“CAR-T”) cell therapy candidates are manufactured in advance with cells from healthy donors, with the goal of enabling broad patient access, rapid patient treatment, and increased manufacturing scale. We use our chRDNA technologies to armor our allogeneic CAR-T cell therapies through multiple genome-editing strategies, such as checkpoint disruption and immune cloaking, to enhance activity against hematologic malignancies. We incorporated in October 2011 as a Delaware corporation and are headquartered in Berkeley, California. We have four wholly owned subsidiaries that hold interests in our equity investments and do not have operating activities. Liquidity We have incurred operating losses and negative cash flows from operations since our inception and we had an accumulated deficit of $ 621.6 million as of March 31, 2026. During the three months ended March 31, 2026, we incurred a net loss of $ 25.1 million and used $ 27.0 million of cash in operating activities. We expect to continue to incur substantial losses, and our ability to achieve and sustain profitability will depend on the successful development, regulatory approval, and commercialization of our CAR-T cell therapy product candidates and on our ability to generate sufficient revenue to support our cost structure. We may never achieve profitability and, unless and until we do, we will need to continue to raise additional capital. Our management expects that existing cash, cash equivalents, and marketable securities of $ 118.6 million as of March 31, 2026, will be sufficient to fund our current operating plan for at least the next 12 months from the date this Quarterly Report on Form 10-Q (“Form 10-Q”) is filed. 2. Summary of Significant Accounting Policies There have been no changes to the significant accounting policies disclosed in Note 2 to the annual consolidated financial statements for the year ended December 31, 2025, included in our Annual Report on Form 10-K (“Form 10-K”). Basis of Presentation and Principles of Consolidation Our unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and include our accounts and the accounts of our wholly owned subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Certain prior period amounts in our consolidated financial statements have been reclassified to conform to current period presentation. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities; the disclosure of contingent assets and liabilities at the date of our unaudited condensed consolidated financial statements; and the reported amounts of revenue, income, and expenses for the applicable reporting period. Significant estimates and assumptions made in the accompanying unaudited condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, stock-based compensation expense, and accrued research and development expenses. Our management evaluates its estimates and assumptions on an ongoing basis using historical experience and various other assumptions that they believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates. 5 Table of Contents Concentrations of Credit Risk and Other Uncertainties Financial instruments that potentially subject us to concentration of credit risk consist of cash and cash equivalents, accounts receivable, contract assets, other receivables, and investments in marketable securities and equity securities. Substantially all our cash and cash equivalents are deposited in accounts at four financial institutions, and our account balances exceed federally insured limits. We mitigate the risks by investing only in high-grade instruments, limiting our exposure to any single issuer, and monitoring the ongoing creditworthiness of these financial institutions and issuers. Third parties that represent 10% or more of our revenue and accounts receivable and contract assets were as follows: Revenue Accounts Receivable and Contract Assets Three Months Ended As of March 31, 2026 As of December 31, 2025 March 31, 2026 March 31, 2025 Party A 25.9 % 26.4 % * * Party B 25.7 % 26.2 % * * Party C 20.6 % 16.8 % 60.4 % 54.5 % Party D * * * 11.8 % Party E * * 11.1 % * Total 72.2 % 69.4 % 71.5 % 66.3 % *Less than 10% We monitor economic conditions to identify facts or circumstances that may indicate if any of our accounts receivable are not collectible or if contract assets should be impaired. No allowance for credit losses or contract asset impairment was recorded as of March 31, 2026, or December 31, 2025. Recent Accounting Pronouncements Not Yet Adopted In November 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in ASU 2024-03 require a public business entity to disclose specific information about certain costs and expenses in the notes to its financial statements for interim and annual reporting periods. The objective of the disclosure requirements is to provide disaggregated information about a public business entity's expenses to help investors (i) better understand the entity's performance, (ii) better assess the entity's prospects for future cash flows, and (iii) compare an entity's performance over time and with that of other entities. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. We are currently evaluating the impact of the adoption of ASU 2024-03. In September 2025, the FASB issued ASU No. 2025-06 - Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The amendments in ASU 2025-06 remove all references to prescriptive and sequential software development stages. This ASU requires entities to begin capitalizing software costs when management authorizes and commits to funding the software project, and it is probable that the project will be completed and the software will be used for its intended purpose. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027, with early adoption permitted. We are currently evaluating the impact of the adoption of ASU 2025-06. In December 2025, the FASB issued ASU 2025-11 - Interim Reporting (Topic 270): Narrow-Scope Improvements. The amendments in ASU 2025-11 provide clarifications intended to improve the consistency and usability of interim disclosure requirements, including a comprehensive listing of required interim disclosures and a new disclosure principle for reporting material events occurring after the most recent annual financial reporting period. ASU 2025-11 is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years, with early adoption permitted. We are currently evaluating the impact of the adoption of ASU 2025-11. 6 Table of Contents 3. Fair Value Measurements and Fair Value of Financial Instruments We classify fair value-based measurements using a three-level hierarchy that prioritizes the inputs used to measure fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1, quoted market prices (unadjusted) in active markets for identical assets or liabilities; Level 2, observable inputs other than quoted market prices included in Level 1, such as quoted market prices for markets that are not active or other inputs that are observable or can be corroborated by observable market data; and Level 3, unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, including certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. We recognize transfers into and out of levels within the fair value hierarchy in the period in which the actual event or change in circumstances that caused the transfer occurs. No such transfers occurred during the three months ended March 31, 2026, and March 31, 2025. Recurring Measurements The following table sets forth our financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): Fair Value Measurements as of March 31, 2026 Total Level 1 Level 2 Level 3 Assets: U.S. Treasury bills $ 63,405 $ 63,405 $ — $ — U.S. government agency bonds 28,498 — 28,498 — Money market fund investments (included in cash and cash equivalents) 12,057 12,057 — — Corporate debt securities 7,685 — 7,685 — Commercial paper 6,982 — 6,982 — Total fair value of assets $ 118,627 $ 75,462 $ 43,165 $ — Fair Value Measurements as of December 31, 2025 Total Level 1 Level 2 Level 3 Assets: U.S. Treasury bills $ 86,964 $ 86,964 $ — $ — U.S. government agency bonds 28,717 — 28,717 — Money market fund investments (included in cash and cash equivalents) 11,361 11,361 — — Corporate debt securities 8,663 — 8,663 — Commercial paper ($ 999 included in cash and cash equivalents) 7,140 — 7,140 — Total fair value of assets $ 142,845 $ 98,325 $ 44,520 $ — 7 Table of Contents The fair value and amortized cost of cash equivalents and available-for-sale marketable securities by major security type as of March 31, 2026, and December 31, 2025, are presented in the following tables (in thousands): As of March 31, 2026 Amortized Cost Basis Unrealized Gains Unrealized Losses Estimated Fair Value U.S. Treasury bills $ 63,404 $ 18 $ ( 17 ) $ 63,405 U.S. government agency bonds 28,512 1 ( 15 ) 28,498 Money market fund investments (included in cash and cash equivalents) 12,057 — — 12,057 Corporate debt securities 7,695 — ( 10 ) 7,685 Commercial paper 6,983 — ( 1 ) 6,982 Total cash equivalents and marketable securities $ 118,651 $ 19 $ ( 43 ) $ 118,627 Classified as: Cash and cash equivalents $ 12,057 Marketable securities, short-term 105,569 Marketable securities, long-term 1,001 Total cash equivalents and marketable securities 118,627 As of December 31, 2025 Amortized Cost Basis Unrealized Gains Unrealized Losses Estimated Fair Value U.S. Treasury bills $ 86,872 $ 92 $ — $ 86,964 U.S. government agency bonds 28,707 12 ( 2 ) 28,717 Money market fund investments (included in cash and cash equivalents) 11,361 — — 11,361 Corporate debt securities 8,663 2 ( 2 ) 8,663 Commercial paper ($ 999 included in cash and cash equivalents) 7,139 1 — 7,140 Total cash equivalents and marketable securities $ 142,742 $ 107 $ ( 4 ) $ 142,845 Classified as: Cash and cash equivalents $ 12,360 Marketable securities, short-term 126,980 Marketable securities, long-term 3,505 Total cash equivalents and marketable securities $ 142,845 We reviewed each of our marketable securities as of March 31, 2026, and December 31, 2025, and concluded that any decline in fair value was not related to credit losses and is recoverable. Accordingly, no allowance for credit losses was recorded and the unrealized losses are reported as a component of accumulated other comprehensive income. 4. Significant Agreements Since December 31, 2025, there have been no material changes to the key terms of our ongoing significant agreements. See Note 4 to the consolidated financial statements included in our Form 10-K for additional information about our ongoing significant agreements. Our ongoing significant agreements may include nonrefundable, upfront payments; annual license maintenance fees; sublicensing fees; obligations to reimburse for patent prosecution and maintenance fees; success payments; regulatory clinical and commercial milestones; and royalty payments. Our obligation to make such payments is contingent on milestones being achieved, licensed products being commercialized, and the agreements remaining in effect. 8 Table of Contents For each of the three-month periods ended March 31, 2026, and March 31, 2025, we recorded $ 0.3 million as research and development expenses related to our license agreements. Patent prosecution and maintenance costs included in general and administrative expenses were $ 0.1 million and $ 0.2 million for the three months ended March 31, 2026, and March 31, 2025, respectively. These amounts include reimbursements of approximately $ 0.3 million and $0.2 million for the three months ended March 31, 2026, and March 31, 2025, respectively. As of March 31, 2026, certain license and assignment agreements included potential future payments from us for development, regulatory, and sales milestones totaling approximately $ 48.9 million. 5. Revenue Disaggregation of Revenue We disaggregate revenue by geographical market based on the location of research and development activities of our licensees and other third parties. The following table is a summary of revenue by geographic location for the three months ended March 31, 2026, and March 31, 2025 (in thousands): Three Months Ended March 31, 2026 2025 United States $ 2,257 $ 2,224 Rest of world 140 129 Total $ 2,397 $ 2,353 For each of the three-month periods ended March 31, 2026, and March 31, 2025, we recognized $ 1.8 million of revenue related to performance obligations satisfied at a point in time, and we recognized $ 0.6 million of revenue related to performance obligations satisfied over time. Contract Balances Accounts receivable relate to our right to consideration for performance obligations completed (or partially completed) for which we have an unconditional right to consideration. Our accounts receivable balances represent amounts we billed to our licensees with invoices outstanding as of the end of a reporting period. Contract assets are rights to consideration in exchange for a license that we have granted to a licensee when the right is conditional on something other than the passage of time. Our contract asset balances represent royalties and milestone payments from our other license agreements that are unbilled as of the end of a reporting period. Contract liabilities consist of deferred revenue and relate to amounts invoiced to, or advance consideration received from, licensees and other third parties that precede our satisfaction of the associated performance obligations. As of March 31, 2026, and December 31, 2025, our deferred revenue balance primarily resulted from the upfront payment received in 2023 relating to our performance obligation to Pfizer Inc. (“Pfizer”). The remaining deferred revenue relates to upfront payments received under license agreements that also include nonrefundable annual license fees, which are accounted for as material rights for license renewals and are recognized at the point in time when annual license fees are paid by the licensees and the renewal periods begin. 9 Table of Contents The following table presents changes in our contract assets and liabilities for the three months ended March 31, 2026 (in thousands): Balance as of December 31, 2025 Additions Deductions Balance as of March 31, 2026 Accounts receivable $ 69 $ 1,709 $ ( 1,551 ) $ 227 Contract assets: Unbilled accounts receivable $ 1,006 $ 691 $ ( 1,006 ) $ 691 Contract liabilities: Deferred revenue, current and long-term $ 3,647 $ 676 $ ( 1,681 ) $ 2,642 For each of the three-month periods ended March 31, 2026, and March 31, 2025, we recognized $ 1.0 million of revenue, which was included in the opening contract liabilities balances at the beginning of the respective periods. Transaction Prices Allocated to Remaining Performance Obligations Remaining performance obligations represent in aggregate the amount of a transaction price that has been allocated to performance obligations not delivered as of the end of a reporting period. The value of transaction prices allocated to remaining unsatisfied performance obligations as of March 31, 2026, and December 31, 2025, were approximately $ 2.6 million and $ 3.6 million, respectively. We expect to recognize approximately $ 1.0 million of remaining performance obligations as revenue in the next 12 months from March 31, 2026, and to recognize the remainder thereafter. Capitalized Contract Acquisition Costs and Fulfillment Costs We did not incur any expenses to obtain our existing contracts, and costs to fulfill those contracts do not generate or enhance our resources. As such, no costs to obtain or fulfill a contract have been capitalized in any period. 6. Balance Sheet Items Property and equipment, net, consisted of the following (in thousands): March 31, 2026 December 31, 2025 Lab equipment $ 15,649 $ 15,636 Leasehold improvements 3,057 3,057 Computer equipment 897 897 Furniture and equipment 697 697 Total property and equipment, gross 20,300 20,287 Less: accumulated depreciation and amortization ( 14,177 ) ( 13,527 ) Property and equipment, net $ 6,123 $ 6,760 Depreciation and amortization expenses related to property and equipment were $ 0.6 million and $ 1.2 million for the three months ended March 31, 2026, and March 31, 2025, respectively. 10 Table of Contents Accrued expenses and other current liabilities consisted of the following (in thousands): March 31, 2026 December 31, 2025 Accrued research and development expenses $ 7,614 $ 6,109 Accrued employee compensation and related expenses 3,712 7,745 Accrued expenses related to sublicensing revenues 983 992 Accrued patent expenses 848 873 Other 732 816 Total $ 13,889 $ 16,535 7 . Related Party Transactions Since December 31, 2025, there have been no new related party transactions. See Note 7 to the consolidated financial statements included in our Form 10-K for additional information about our related parties. Pfizer Investment During the three months ended March 31, 2025, we recognized $ 0.6 million of revenue from our Information Rights Agreement with Pfizer, dated June 29, 2023, pursuant to which we had originally allocated $ 7.5 million as a contract with a customer under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”). Pfizer ceased to be a related party as of December 31, 2025. 8. Commitments and Contingencies Research, Manufacturing, and License Agreements We enter into various agreements in the ordinary course of business, such as those with contract manufacturing organizations (“CMOs”), suppliers, contract research organizations (“CROs”), clinical trial sites, licensors, assignors, and the like. These agreements provide for termination by either party in certain circumstances, generally with less than one-year notice and are, therefore, cancellable contracts and, if cancelled, are not anticipated to have a material effect on our unaudited condensed consolidated financial condition, results of operations, or cash flows. Some of these agreements include contingent payments that will become payable if and when certain development, regulatory, clinical, and/or commercial milestones are achieved by us. As of March 31, 2026, satisfaction and timing of such contingent payments are uncertain and thus cannot be reasonably estimated. Guarantees and Indemnifications In the ordinary course of business, we enter into agreements that contain a variety of representations and warranties and provide for certain indemnifications by us. Our exposure under these agreements is unknown because claims may be made against us in the future. As of March 31, 2026, and December 31, 2025, we did not have any material indemnification claims that were probable or reasonably possible, and consequently, we have not recorded related liabilities. Litigation From time to time, we may become involved in litigation arising in the ordinary course of business. We record a liability for such litigation when it is probable that future losses will be incurred and if such losses can be reasonably estimated. Significant judgment by us is required to determine both probability and the estimated amount. 11 Table of Contents 9. Common Stock Shares of our c ommon stock reserved for future issuances consisted of the following: As of March 31, 2026 As of December 31, 2025 Stock options, issued and outstanding 15,895,762 12,511,072 Shares of common stock, authorized for future issuances 9,338,658 9,192,963 Shares committed under ESPP 3,029,080 2,426,055 Unvested RSUs 3,019,668 2,173,234 Total shares of common stock reserved for future issuances 31,283,168 26,303,324 Shelf Registration Statement On May 8, 2025, we filed a shelf registration statement on Form S-3 (“2025 Shelf Registration Statement”), which was declared effective by the SEC on May 14, 2025. Pursuant to the 2025 Shelf Registration Statement, we may, from time to time, sell up to $ 300.0 million of common stock, preferred stock, debt securities, warrants, rights, or units comprised of any combination thereof (including the $ 100.0 million of common stock reserved under the 2025 Shelf Registration Statement for our at-the-market equity offering program described below). As of March 31, 2026, we had $ 293.4 million available for sale under the 2025 Shelf Registration Statement. At-the-Market Equity Offering Program On August 9, 2022, we entered into an at-the-market Open Market Sale Agreement SM (“ATM Sales Agreement”) with Jefferies LLC (“Jefferies”) in connection with a prior shelf registration statement. With the effectiveness of the 2025 Shelf Registration Statement, we refreshed our at-the-market equity offering program under the ATM Sales Agreement. We may, from time to time, sell and issue shares of our common stock, through Jefferies as sales agent under the ATM Sales Agreement, having an aggregate offering price of up to $ 100.0 million in gross proceeds under the 2025 Shelf Registration Statement. During the three months ended March 31, 2026, we sold 1,078,768 shares of our common stock at an average price of $ 2.11 per share, in accordance with the ATM Sales Agreement and the 2025 Shelf Registration Statement, for aggregate gross proceeds of $ 2.3 million ($ 2.2 million net of offering expenses). We did not sell any shares of our common stock under the ATM Sales Agreement during the three months ended March 31, 2025. As of March 31, 2026, $ 93.4 million of shares of our common stock remained available for sale under the 2025 Shelf Registration Statement pursuant to the ATM Sales Agreement. 10. Stock-Based Compensation Equity Incentive Plans In July 2021, our board of directors adopted, and our stockholders approved, the 2021 Equity Incentive Plan (“2021 Plan”) that became effective on July 22, 2021. As of March 31, 2026, we had 9,338,658 shares available for issuance under the 2021 Plan. 12 Table of Contents Stock Options The following table summarizes stock option activity, including performance-based stock options (“PBSOs”), under our equity incentive plans for the three months ended March 31, 2026: Stock Options and PBSOs Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) (1) Outstanding as of December 31, 2025 12,511,072 $ 5.49 7.6 $ 466 Options granted 3,472,927 1.80 Options exercised ( 6,200 ) 1.41 Options cancelled or forfeited ( 82,037 ) 5.39 Outstanding as of March 31, 2026 15,895,762 $ 4.68 7.9 $ 1,703 Exercisable as of March 31, 2026 7,606,050 $ 6.98 6.6 $ 475 Vested and expected to vest as of March 31, 2026 15,895,762 $ 4.68 7.9 $ 1,703 (1) The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the estimated fair value of the underlying common stock as of the end of each reporting period referenced above. Grant Date Fair Value of Stock Options During the three months ended March 31, 2026, and March 31, 2025, we granted 3,472,927 and 3,335,888 stock options, respectively, under the 2021 Plan to employees with a weighted average grant date fair value of $ 1.36 and $ 1.07 , respectively. We estimated the fair value of each employee stock option award on the grant date using the Black-Scholes option-pricing model based on the following assumptions: Three Months Ended March 31, 2026 2025 Volatility 89.9 % to 90.6 % 86.1 % to 89.7 % Expected term (in years) 5.0 to 6.0 5.0 to 6.0 Risk-free interest rate 3.7 % to 3.8 % 4.3 % to 4.6 % Expected dividend yield 0.0 % 0.0 % As of March 31, 2026, there was $ 13.4 million of unrecognized stock-based compensation expense related to employee stock options that is expected to be recognized over a weighted-average period of 2.8 years. Grant Date Fair Value of PBSOs On July 21, 2025, we granted 1,092,165 PBSOs under the 2021 Plan to each of our officers with a weighted average grant date fair value of $ 1.00 . We estimated the fair value of each PBSO on the grant date using the Black-Scholes option-pricing model based on a volatility of 88.7 %, expected term of 1.9 years, risk-free interest rate of 3.9 %, and expected dividend yield of 0.0 %. Vesting of the PBSOs is conditioned on achievement of certain clinical development milestones during a two-year performance period ending June 30, 2027, and contingent on each executive officer’s continued employment on the vesting dates. As of March 31, 2026, there were 1,092,165 PBSOs outstanding with a weighted average grant date fair value of $ 1.00 . As of March 31, 2026, we have concluded that it is not yet deemed probable, as required by ASC Topic 718 Compensation - Stock Compensation, that the clinical milestones will be achieved, and as such, no stock-based compensation expense has been recorded for PBSOs. As of March 31, 2026, there was $ 1.1 million of unrecognized stock-based compensation expense related to PBSOs, which will be recognized if the awards are deemed to be probable of vesting. 13 Table of Contents Restricted Stock Units (“RSUs”) During the three months ended March 31, 2026, we granted 1,220,599 RSUs under the 2021 Plan to employees. A summary of the status of and change in unvested RSUs as of March 31, 2026, was as follows: Number of Shares Underlying Outstanding RSUs Weighted-Average Grant Date Fair Value per RSU Unvested, December 31, 2025 2,173,234 $ 2.74 Granted 1,220,599 1.80 Vested ( 374,165 ) 3.45 Forfeited — — Unvested, March 31, 2026 3,019,668 $ 2.27 As of March 31, 2026, the total unrecognized stock-based compensation expense related to unvested RSUs was $ 6.1 million, which is expected to be recognized over the remaining weighted-average vesting period of 2.9 years. Employee Stock Purchase Plan (“ESPP”) In July 2021, our board of directors adopted, and our stockholders approved, the ESPP, which became effective on July 22, 2021. We issued 1,454,552 shares of common stock under the ESPP as of March 31, 2026. We recorded $ 0.1 million in accrued liabilities related to contributions withheld as of March 31, 2026. Stock-Based Compensation Expense We recorded stock-based compensation expense related to employee equity-based awards grants as follows (in thousands): Three Months Ended March 31, 2026 2025 Research and development $ 1,125 $ 1,743 General and administrative 1,232 2,139 Total $ 2,357 $ 3,882 The above stock-based compensation expense related to the following equity-based awards (in thousands): Three Months Ended March 31, 2026 2025 Stock options $ 1,666 $ 3,175 RSUs 574 585 ESPP 117 122 Total $ 2,357 $ 3,882 11. Income Taxes No income tax expense was recorded during each of the three-month periods ended March 31, 2026, and March 31, 2025 due to our operating losses. 14 Table of Contents 12. Net Loss Per Share The following table sets forth the computation of the basic and diluted net loss per share (in thousands, except share and per share amounts): Three Months Ended March 31, 2026 2025 Numerator: Net loss $ ( 25,085 ) $ ( 39,991 ) Denominator: Weighted-average common shares outstanding used to compute net loss per share, basic and diluted 95,861,716 92,679,493 Net loss per share, basic and diluted $ ( 0.26 ) $ ( 0.43 ) Because we were in a net loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods, as the inclusion of all common stock equivalents outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows: As of March 31, 2026 As of March 31, 2025 Stock options outstanding 15,895,762 14,022,265 RSUs issued and outstanding 3,019,668 2,217,789 Shares committed under ESPP 324,132 509,727 19,239,562 16,749,781 13. Segment Information We operate and manage our business as one reportable segment and one operating segment, which is the business of developing allogeneic CAR-T cell therapies. Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance; the CODM is our president and chief executive officer. Our CODM assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is also reported on our consolidated statements of operations. The measure of segment assets is reported on our consolidated balance sheets as total consolidated assets. All our material long-lived assets are located in the United States. Our CODM uses consolidated net loss to evaluate our spending and monitor our budget versus actual results to assess performance of the segment and to allocate resources across our company. Factors used in determining the reportable segment include the nature of our operating activities, our company’s organizational and reporting structures, and the type of information reviewed by our CODM to allocate resources and evaluate financial performance. 15 Table of Contents The following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable segment for the periods indicated: Three Months Ended March 31, 2026 2025 Licensing and other third-party revenue $ 2,397 $ 2,353 Less: Research and development: External costs 10,690 21,859 Internal costs (1) 8,179 10,877 Total research and development 18,869 32,736 General and administrative (2) 6,802 7,484 Other segment items (3) 3,006 4,712 Other income, net ( 1,195 ) ( 2,588 ) Segment and consolidated net loss $ ( 25,085 ) $ ( 39,991 ) (1) Research and development internal costs for the three months ended March 31, 2026, and March 31, 2025, exclude $ 1.1 million and $ 1.7 million of stock-based compensation expense, respectively, and $ 0.6 million and $ 1.1 million of depreciation and amortization expense, respectively. (2) General and administrative expense for the three months ended March 31, 2026, and March 31, 2025, exclude $ 1.2 million and $ 2.1 million of stock-based compensation expense, respectively, and less than $ 0.1 million and $ 0.1 million of depreciation and amortization expense, respectively. (3) Other segment items for the three-month periods ended March 31, 2026, and March 31, 2025, include stock-based compensation and depreciation and amortization. 16 Table of Contents